Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod

@article{deJong2018IntracerebralLD,
  title={Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod},
  author={Brigit A de Jong and Zo{\'e} L. E. van Kempen and Mike P. Wattjes and Patrick M. Smit and Laura Peferoen and Da Berry and Martine E. D. Chamuleau and Daphne de Jong},
  journal={Neurology{\textregistered} Neuroimmunology \& Neuroinflammation},
  year={2018},
  volume={5}
}
Fingolimod, an oral sphingosine 1-phosphate (S1P) receptor modulator, is an effective oral immune therapy for treatment of relapsing-remitting MS (RRMS).1 Development of solid malignancies was observed in large randomized phase-3 trials examining the efficacy and safety of fingolimod in patients with RRMS.1 In this article, we present a patient who developed a primary central nervous system T-cell lymphoproliferative disorder during fingolimod treatment. 
6 Citations

BASAL CELL CARCINOMA AND SQUAMOUS CELL CARCINOMA IN A PATIENT TREATED WITH FINGOLIMOD FOR MULTIPLE SCLEROSIS - A CASE REPORT AND LITERATURE REVIEW.

Dermatological examination should be performed at the beginning and during treatment with fingolimod and patient education are crucial during treatment, which allows achieving a good therapeutic effect, thus minimizing the risk of malignancy and enabling its early detection and cure.

Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications

The current role of MRI in safety monitoring during pharmacovigilance of patients treated with (selective) immune suppressive therapies for MS is discussed.

Fingolimod

  • Reactions Weekly
  • 2019

References

SHOWING 1-8 OF 8 REFERENCES

Fingolimod-Associated Intracerebral Lymphoproliferative Disorder.

An atypical case of intracerebral plasmacytic lymphoproliferative disorder in a 47 years old patient on fingolimod is described and heightened clinical suspicion and early recognition of these serious adverse events remain crucial.

Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.

A 39-year-old woman treated for relapsing-remitting multiple sclerosis for 2 years who then developed a bilateral conjunctival mucosa-associated lymphoid tissue lymphoma is described, the first case of ocular adnexal lymphoma presumed to be due to fingolimod.

Fingolimod for multiple sclerosis.

A 37-year-old man with multiple sclerosis has recurrent disease activity despite several previous therapies. Treatment with fingolimod is recommended. Fingolimod blocks the egress of lymphocytes from

Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension

Results in a small number of patients suggest lack of benefit in AQP4 antibody-positive patients, and fingolimod treatment for up to 12 months was associated with maintained or improved efficacy and a manageable safety profile, consistent with that previously seen.

Fingolimod for relapsing-remitting multiple sclerosis.

Comparing fingolimod administered at the approved dose of 0.5 mg to placebo, it was found that the drug at 24 months increased the probability of being relapse-free, but it might lead to little or no difference in preventing disability progression.

Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to FTY720 during neuroinflammation.

It is found that mice carrying a phosphorylation-defective S1pr1 gene [S1PR1(S5A) mice] were refractory to FTY720 treatment in MOG35-55-immunized and Th17-mediated experimental autoimmune encephalomyelitis (EAE) models, suggesting that cell type-specific therapies may enhance therapeutic efficacy in MS.

Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod

Causality of fingolimod is indicated by the fact that the skin lesions appeared after commencement of treatment and resolved after discontinuation of therapy.

ff ects of sphingosine - 1 - phosphate receptor 1 phosphorylation in response to FTY 720 during neuroin fl ammation

  • JCI Insight
  • 2016